These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 34587971

  • 21. Initiating Intramuscular Depot Medroxyprogesterone Acetate Increases Frequencies of Th17-like Human Immunodeficiency Virus Target Cells in the Genital Tract of Women in South Africa: A Randomized Trial.
    Bunjun R, Ramla TF, Jaumdally SZ, Noël-Romas L, Ayele H, Brown BP, Gamieldien H, Harryparsad R, Dabee S, Nair G, Onono M, Palanee-Phillips T, Scoville CW, Heller KB, Baeten JM, Bosinger SE, Burgener A, Passmore JS, Jaspan H, Heffron R.
    Clin Infect Dis; 2022 Nov 30; 75(11):2000-2011. PubMed ID: 35941737
    [Abstract] [Full Text] [Related]

  • 22. Influence of Hormonal Contraceptive Use and HIV on Cervicovaginal Cytokines and Microbiota in Malawi.
    Haddad LB, Tang JH, Davis NL, Kourtis AP, Chinula L, Msika A, Tegha G, Hosseinipour MC, Nelson JAE, Hobbs MM, Gajer P, Ravel J, De Paris K.
    mSphere; 2023 Feb 21; 8(1):e0058522. PubMed ID: 36622252
    [Abstract] [Full Text] [Related]

  • 23. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
    Kaislasuo J, Heikinheimo O, Lähteenmäki P, Suhonen S.
    Hum Reprod; 2015 Jul 21; 30(7):1580-8. PubMed ID: 25990577
    [Abstract] [Full Text] [Related]

  • 24. Contraceptive Continuation and Experiences Obtaining Implant and IUD Removal Among Women Randomized to Use Injectable Contraception, Levonorgestrel Implant, and Copper IUD in South Africa and Zambia.
    Cartwright AF, Callahan RL, Beksinska M, Kasaro MP, Tang JH, Milford C, Wong C, Velarde M, Maphumulo V, Fawzy M, Chinyama M, Chabu E, Mudenda M, Smit J.
    Stud Fam Plann; 2023 Jun 21; 54(2):379-401. PubMed ID: 36727169
    [Abstract] [Full Text] [Related]

  • 25. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system.
    Suvisaari J, Lähteenmäki P.
    Contraception; 1996 Oct 21; 54(4):201-8. PubMed ID: 8922872
    [Abstract] [Full Text] [Related]

  • 26. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
    Sivin I, Stern J, Diaz J, Diaz MM, Faundes A, el Mahgoub S, Diaz S, Pavez M, Coutinho E, Mattos CE.
    Contraception; 1987 Mar 21; 35(3):245-55. PubMed ID: 3111785
    [Abstract] [Full Text] [Related]

  • 27. Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic.
    Bahamondes L, Bottura BF, Bahamondes MV, Gonçalves MP, Correia VM, Espejo-Arce X, Sousa MH, Monteiro I, Fernandes A.
    Hum Reprod; 2014 Oct 10; 29(10):2163-70. PubMed ID: 25085802
    [Abstract] [Full Text] [Related]

  • 28. Effects of the copper intrauterine device versus injectable progestin contraception on pregnancy rates and method discontinuation among women attending termination of pregnancy services in South Africa: a pragmatic randomized controlled trial.
    Hofmeyr GJ, Singata-Madliki M, Lawrie TA, Bergel E, Temmerman M.
    Reprod Health; 2016 Apr 18; 13():42. PubMed ID: 27091008
    [Abstract] [Full Text] [Related]

  • 29. Systems analysis reveals differential expression of endocervical genes in African women randomized to DMPA-IM, LNG implant or cu-IUD.
    Gupta PM, Balle C, Tharp GK, Nelson SA, Gasper MA, Brown B, Alisoltani A, Onono M, Palanee-Phillips T, Nair G, Ayele H, Noel-Romas L, Passmore JS, Burgener AD, Heffron R, Jaspan HB, Bosinger SE.
    Clin Immunol; 2023 Oct 18; 255():109750. PubMed ID: 37660744
    [Abstract] [Full Text] [Related]

  • 30. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use.
    Modesto W, de Nazaré Silva dos Santos P, Correia VM, Borges L, Bahamondes L.
    Eur J Contracept Reprod Health Care; 2015 Feb 18; 20(1):57-63. PubMed ID: 25160484
    [Abstract] [Full Text] [Related]

  • 31. [Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil].
    Yela DA, Monteiro IM, Bahamondes LG, Del Castillo S, Bahamondes MV, Fernandes A.
    Rev Assoc Med Bras (1992); 2006 Feb 18; 52(1):32-6. PubMed ID: 16622536
    [Abstract] [Full Text] [Related]

  • 32. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study.
    Luukkainen T, Allonen H, Haukkamaa M, Holma P, Pyörälä T, Terho J, Toivonen J, Batar I, Lampe L, Andersson K.
    Contraception; 1987 Aug 18; 36(2):169-79. PubMed ID: 3123132
    [Abstract] [Full Text] [Related]

  • 33. Genital inflammatory status and the innate immune response to contraceptive initiation.
    Radzey N, Harryparsad R, Meyer B, Chen PL, Gao X, Morrison C, Taku O, Williamson AL, Mehou-Loko C, Lefebvre d'Hellencourt F, Buck G, Smit J, Strauss J, Nanda K, Ahmed K, Beksinska M, Serrano M, Bailey V, Masson L, Deese J.
    Am J Reprod Immunol; 2022 Aug 18; 88(2):e13542. PubMed ID: 35394678
    [Abstract] [Full Text] [Related]

  • 34. Hormonal contraception and HIV acquisition among women: an updated systematic review.
    Curtis KM, Hannaford PC, Rodriguez MI, Chipato T, Steyn PS, Kiarie JN.
    BMJ Sex Reprod Health; 2020 Jan 18; 46(1):8-16. PubMed ID: 31919239
    [Abstract] [Full Text] [Related]

  • 35. Effects of injectable contraception with depot medroxyprogesterone acetate or norethisterone enanthate on estradiol levels and menstrual, psychological and behavioral measures relevant to HIV risk: The WHICH randomized trial.
    Singata-Madliki M, Smit J, Beksinska M, Balakrishna Y, Avenant C, Beesham I, Seocharan I, Batting J, Hapgood JP, Hofmeyr GJ.
    PLoS One; 2024 Jan 18; 19(3):e0295764. PubMed ID: 38530848
    [Abstract] [Full Text] [Related]

  • 36. Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine-device use.
    Christelle K, Norhayati MN, Jaafar SH.
    Cochrane Database Syst Rev; 2022 Aug 26; 8(8):CD006034. PubMed ID: 36017945
    [Abstract] [Full Text] [Related]

  • 37. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
    Steinauer JE, Upadhyay UD, Sokoloff A, Harper CC, Diedrich JT, Drey EA.
    Contraception; 2015 Dec 26; 92(6):553-9. PubMed ID: 26093190
    [Abstract] [Full Text] [Related]

  • 38. Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial.
    Chinula L, Nelson JAE, Wiener J, Tang JH, Hurst S, Tegha G, Msika A, Ellington S, Hosseinipour MC, Mataya R, Haddad LB, Kourtis AP.
    Contraception; 2018 Sep 26; 98(3):193-198. PubMed ID: 29746813
    [Abstract] [Full Text] [Related]

  • 39. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement.
    Bahamondes L, Brache V, Ali M, Habib N, WHO study group on contraceptive implants for women.
    Contraception; 2018 Sep 26; 98(3):181-187. PubMed ID: 29777663
    [Abstract] [Full Text] [Related]

  • 40. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
    Luukkainen T, Toivonen J.
    Contraception; 1995 Nov 26; 52(5):269-76. PubMed ID: 8585882
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.